medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2022, Number 1

<< Back Next >>

Medicina & Laboratorio 2022; 26 (1)

Hypersensitivity reactions to chemotherapeutics and biologics

Martínez-Castillo DM, Ardila-Herrera JC, Calle-Álvarez AM, Chinchilla-Mejía CF

Language: Spanish
References: 76
Page: 63-80
PDF size: 125.80 Kb.


ABSTRACT

Drug reactions have increased over time, they now imply a significant burden of disease mainly in hospital services. Chemotherapeutic and biological agents are drugs frequently used in different rheumatological diseases and neoplasms. Hypersensitivity reactions to chemotherapeutic and monoclonal drugs impact the quality of life, prognosis and mortality of patients with autoimmune diseases and cancer, that is why they must be recognized and managed by a multidisciplinary team. Desensitization is a therapeutic tool that offers great benefits to patients with hypersensitivity reactions, allowing them to use first-line drugs in a safe and cost-effective manner, with a significant impact on patient morbidity and mortality. The objective of this article was to review the most recent information and evidence on hypersensitivity reactions to chemotherapeutics and biologics, and data on desensitization options with these drugs and their outcome.


REFERENCES

  1. Jiménez ÓE, Navarro-Pemán C, González-Rubio F, Lanuza-Giménez FJ, Montesa-Lou C.Análisis de la incidencia y de las característicasclínicas de las reacciones adversas a medicamentosde uso humano en el medio hospitalario.Rev Esp Salud Publica 2017;91:1-17.

  2. Organización Mundial de la Salud. Vigilanciade la seguridad de los medicamentos. Sistemade notificación para el público en general.Ginebra, Suiza: OMS; 2012. Acceso 15 de juliode 2021. Disponible en https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHO-UMC_ReportingGeneralPublic-ESPGRA3Final.pdf.

  3. Bush T. Adverse drug reactions in hospitalizedpatients. JAMA 1998;280:1742-1744.

  4. Gomes ER, Demoly P. Epidemiology of hypersensitivitydrug reactions. Curr Opin AllergyClin Immunol 2005;5:309-316. https://doi.org/10.1097/01.all.0000173785.81024.33.

  5. Thong BY, Tan TC. Epidemiology and riskfactors for drug allergy. Br J Clin Pharmacol2011;71:684-700. https://doi.org/10.1111/j.1365-2125.2010.03774.x.

  6. Jares EJ, Sánchez-Borges M, Cardona-VillaR, Ensina LF, Arias-Cruz A, Gómez M, et al.Multinational experience with hypersensitivitydrug reactions in Latin America. Ann AllergyAsthma Immunol 2014;113:282-289. https://doi.org/10.1016/j.anai.2014.06.019.

  7. Thong BY, Leong KP, Tang CY, Chng HH.Drug allergy in a general hospital: Resultsof a novel prospective inpatient reportingsystem. Ann Allergy Asthma Immunol2003;90:342-347. https://doi.org/10.1016/s1081-1206(10)61804-2.

  8. Giavina-Bianchi P, Jares E, Aun MV, ThongB. Drug hypersensitivity reactions in the Americas:Similarities and differences. Ann AllergyAsthma Immunol 2019;122:447-448. https://doi.org/10.1016/j.anai.2019.02.007.

  9. Gülsen A, Wedi B, Jappe U. Hypersensitivityreactions to biologics (part I): allergy as animportant differential diagnosis in compleximmune-derived adverse events. AllergoJ 2020;29:32-61. https://doi.org/10.1007/s15007-020-2550-1.

  10. Hong D, Sloane DE. Hypersensitivity to monoclonalantibodies used for cancer and inflammatoryor connective tissue diseases. Ann AllergyAsthma Immunol 2019;123:35-41. https://doi.org/10.1016/j.anai.2019.04.015.

  11. Patel SV, Khan DA. Adverse reactions to biologictherapy. Immunol Allergy Clin North Am2017;37:397-412. https://doi.org/10.1016/j.iac.2017.01.012.

  12. Sala-Cunill A, Luengo O, Cardona V. Biologicsand anaphylaxis. Curr Opin Allergy Clin Immunol2019;19:439-446. https://doi.org/10.1097/aci.0000000000000550.

  13. Quercia O, Emiliani F, Foschi FG, Stefanini GF.Adalimumab desensitization after anaphylacticreaction. Ann Allergy Asthma Immunol2011;106:547-548. https://doi.org/10.1016/j.anai.2011.03.014.

  14. Soyer O, Demir S, Bilginer Y, Batu ED, SonmezHE, Arıcı ZS, et al. Severe hypersensitivityreactions to biological drugs in children withrheumatic diseases. Pediatr Allergy Immunol2019;30:833-840. https://doi.org/10.1111/pai.13114.

  15. Akarsu A, Soyer O, Sekerel BE. Hypersensitivityreactions to biologicals: From bench to bedside.Curr Treat Options Allergy 2020;7:71-83.https://doi.org/10.1007/s40521-020-00242-2.

  16. Sanchez-Piedra C, Hernández-Miguel MV,Manero J, Roselló R, Sánchez-Costa JT, Rodríguez-Lozano C, et al. Objetivos y metodologíade la fase III de BIOBADASER. Reumatol Clin2019;15:229-236. https://doi.org/10.1016/j.reuma.2017.08.001.

  17. Vultaggio A, Castells MC. Hypersensitivityreactions to biologic agents. Immunol AllergyClin North Am 2014;34:615-632. https://doi.org/10.1016/j.iac.2014.04.008.

  18. Vultaggio A, Matucci A, Parronchi P, Rossi O,Palandri F, Romagnani S, et al. Safety and tolerabilityof infliximab therapy: Suggestions andcriticisms based on wide clinical experience. IntJ Immunopathol Pharmacol 2008;21:367-374.https://doi.org/10.1177/039463200802100214.

  19. Pichler WJ. Adverse side-effects to biologicalagents. Allergy 2006;61:912-920. https://doi.org/10.1111/j.1398-9995.2006.01058.x.

  20. Chitnavis M, Stein DJ, Commins S, SchuylerAJ, Behm B. First-dose anaphylaxis to infliximab:a case of mammalian meat allergy. JAllergy Clin Immunol Pract 2017;5:1425-1426.https://doi.org/10.1016/j.jaip.2017.04.044.

  21. Arnold DF, Misbah SA. Cetuximab-inducedanaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med2008;358:2735-2736. https://doi.org/10.1056/NEJMc080834.

  22. Price KS, Hamilton RG. Anaphylactoid reactionsin two patients after omalizumab administrationafter successful long-term therapy.Allergy Asthma Proc 2007;28:313-319. https://doi.org/10.2500/aap.2007.28.3003.

  23. Perino E, Freymond N, Devouassoux G, NicolasJF, Berard F. Xolair-induced recurrent anaphylaxisthrough sensitization to the excipientpolysorbate. Ann Allergy Asthma Immunol2018;120:664-666. https://doi.org/10.1016/j.anai.2018.02.018.

  24. Corominas M, Gastaminza G, Lobera T. Hypersensitivityreactions to biological drugs. J InvestigAllergol Clin Immunol 2014;24:212-225.

  25. del Carmen-Sancho M, Breslow R, SloaneD, Castells M. Desensitization for hypersensitivityreactions to medications. Chem ImmunolAllergy 2012;97:217-233. https://doi.org/10.1159/000335637.

  26. Khan DA. Hypersensitivity and immunologicreactions to biologics: opportunities forthe allergist. Ann Allergy Asthma Immunol2016;117:115-120. https://doi.org/10.1016/j.anai.2016.05.013.

  27. Wing M. Monoclonal antibody first dose cytokinerelease syndromes-mechanisms and prediction.J Immunotoxicol 2008;5:11-15. https://doi.org/10.1080/15476910801897433.

  28. Yildizhan E, Kaynar L. Cytokine release syndrome.J Oncol Sci 2018;4:134-141. https://doi.org/10.1016/j.jons.2018.09.002.

  29. Reber LL, Hernandez JD, Galli SJ. Thepathophysiology of anaphylaxis. J AllergyClin Immunol 2017;140:335-348. https://doi.org/10.1016/j.jaci.2017.06.003.

  30. Isabwe GAC, Garcia-Neuer M, de Las Vecillas-Sanchez L, Lynch DM, Marquis K, Castells M.Hypersensitivity reactions to therapeutic monoclonalantibodies: Phenotypes and endotypes.J Allergy Clin Immunol 2018;142:159-170.https://doi.org/10.1016/j.jaci.2018.02.018.

  31. Bavbek S, Ataman Ş, Akıncı A, Castells M.Rapid subcutaneous desensitization for themanagement of local and systemic hypersensitivityreactions to etanercept and adalimumabin 12 patients. J Allergy Clin Immunol Pract2015;3:629-632. https://doi.org/10.1016/j.jaip.2015.01.009.

  32. O'Meara S, Nanda KS, Moss AC. Antibodiesto infliximab and risk of infusion reactions in patientswith inflammatory bowel disease: a systematicreview and meta-analysis. Inflamm BowelDis 2014;20:1-6. https://doi.org/10.1097/01.MIB.0000436951.80898.6d.

  33. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment withrituximab. Ann Oncol 2002;13:1948-1950.https://doi.org/10.1093/annonc/mdf350.

  34. Urosevic-Maiwald M, Harr T, French LE,Dummer R. Stevens-Johnson syndrome andtoxic epidermal necrolysis overlap in a patientreceiving cetuximab and radiotherapyfor head and neck cancer. Int J Dermatol2012;51:864-867. https://doi.org/10.1111/j.1365-4632.2011.05356.x.

  35. Karmacharya P, Poudel DR, Pathak R, DonatoAA, Ghimire S, Giri S, et al. Rituximab-inducedserum sickness: A systematic review. SeminArthritis Rheum 2015;45:334-340. https://doi.org/10.1016/j.semarthrit.2015.06.014.

  36. Maggi E, Vultaggio A, Matucci A. Acute infusionreactions induced by monoclonal antibodytherapy. Expert Rev Clin Immunol 2011;7:55-63. https://doi.org/10.1586/eci.10.90.

  37. Vitte J, Amadei L, Gouitaa M, Mezouar S, ZieleskiewiczL, Albanese J, et al. Paired acutebaselineserum tryptase levels in perioperativeanaphylaxis: An observational study. Allergy2019;74:1157-1165. https://doi.org/10.1111/all.13752.

  38. Brown SG. Clinical features and severity gradingof anaphylaxis. J Allergy Clin Immunol2004;114:371-376. https://doi.org/10.1016/j.jaci.2004.04.029.

  39. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skintest concentrations for systemically administereddrugs -- an ENDA/EAACI Drug Allergy InterestGroup position paper. Allergy 2013;68:702-712. https://doi.org/10.1111/all.12142.

  40. Hong DI, Dioun AF. Indications, protocols, andoutcomes of drug desensitizations for chemotherapyand monoclonal antibodies in adults andchildren. J Allergy Clin Immunol Pract 2014;2:13-19. https://doi.org/10.1016/j.jaip.2013.11.007.

  41. Bonamichi-Santos R, Castells M. Diagnosesand management of drug hypersensitivity andanaphylaxis in cancer and chronic inflammatorydiseases: Reactions to taxanes and monoclonalantibodies. Clin Rev Allergy Immunol2018;54:375-385. https://doi.org/10.1007/s12016-016-8556-5.

  42. Castells MC. Anaphylaxis to chemotherapyand monoclonal antibodies. Immunol AllergyClin North Am 2015;35:335-348. https://doi.org/10.1016/j.iac.2015.01.011.

  43. Chabner BA, Roberts TG. Chemotherapy andthe war on cancer. Nat Rev Cancer 2005;5:65-72. https://doi.org/10.1038/nrc1529.

  44. Picard M, Castells MC. Re-visiting hypersensitivityreactions to taxanes: A comprehensivereview. Clin Rev Allergy Immunol2015;49:177-191. https://doi.org/10.1007/s12016-014-8416-0.

  45. Turgay-Yagmur I, Guzelkucuk Z, Yarali N, OzyorukD, Toyran M, Civelek E, et al. Evaluationof hypersensitivity reactions to cancer chemotherapeuticagents in pediatric patients. Ann AllergyAsthma Immunol 2020;124:350-356. https://doi.org/10.1016/j.anai.2020.01.010.

  46. Henry A, Charpiat B, Perol M, Vial T, de SaintHilaire PJ, Descotes J. Paclitaxel hypersensitivityreactions: assessment of the utility of a test-doseprogram. Cancer J 2006;12:237-245. https://doi.org/10.1097/00130404-200605000-00013.

  47. Ratanajarusiri T, Sriuranpong V, SitthideatphaiboonP, Poovoravan N, Vinayanuwat C, ParinyanitikulN, et al. A Difference in the incidencesof hypersensitivity reactions to original and generictaxanes. Chemotherapy 2017;62:134-139.https://doi.org/10.1159/000450748.

  48. Koshiba H, Hosokawa K, Kubo A, Miyagi Y,Oda T, Miyagi Y, et al. Incidence of carboplatin-related hypersensitivity reactions in Japanesepatients with gynecologic malignancies. Int JGynecol Cancer 2009;19:460-465. https://doi.org/10.1111/IGC.0b013e3181a1bf2e.

  49. Parel M, Ranchon F, Nosbaum A, You B, VantardN, Schwiertz V, et al. Hypersensitivity tooxaliplatin: clinical features and risk factors.BMC Pharmacol Toxicol 2014;15:1. https://doi.org/10.1186/2050-6511-15-1.

  50. Polyzos A, Tsavaris N, Gogas H, Souglakos J,Vambakas L, Vardakas N, et al. Clinical featuresof hypersensitivity reactions to oxaliplatin: a10-year experience. Oncology 2009;76:36-41.https://doi.org/10.1159/000178163.

  51. Sohn KH, Kang DY, Kim JY, Lee SY, Lee KH,Han SW, et al. Incidence and risk of oxaliplatin-induced hypersensitivity in patients withasymptomatic prior exposure: A prospectiveobservational study. J Allergy Clin ImmunolPract 2018;6:1642-1648.e1642. https://doi.org/10.1016/j.jaip.2017.12.026.

  52. Tham EH, Cheng YK, Tay MH, AlcasabasAP, Shek LP. Evaluation and managementof hypersensitivity reactions to chemotherapyagents. Postgrad Med J 2015;91:145-150. https://doi.org/10.1136/postgradmedj-2014-132686.

  53. Demoly P, Adkinson NF, Brockow K, CastellsM, Chiriac AM, Greenberger PA, et al. InternationalConsensus on drug allergy. Allergy2014;69:420-437. https://doi.org/10.1111/all.12350.

  54. Caiado J, Venemalm L, Pereira-Santos MC,Costa L, Barbosa MP, Castells M. Carboplatin-,oxaliplatin-, and cisplatin-specific IgE:cross-reactivity and value in the diagnosis ofcarboplatin and oxaliplatin allergy. J AllergyClin Immunol Pract 2013;1:494-500. https://doi.org/10.1016/j.jaip.2013.06.002.

  55. Kolomeyevskaya NV, Lele SB, Miller A, RiebandtGC, Blum BL, Odunsi KO, et al. Oxaliplatinis a safe alternative option for patientswith recurrent gynecologic cancers after hypersensitivityreaction to Carboplatin. Int JGynecol Cancer 2015;25:42-48. https://doi.org/10.1097/igc.0000000000000307.

  56. Zweizig S, Roman LD, Muderspach LI. Deathfrom anaphylaxis to cisplatin: a case report.Gynecol Oncol 1994;53:121-122. https://doi.org/10.1006/gyno.1994.1098.

  57. Rose PG, Metz C, Link N. Desensitizationwith oxaliplatin in patients intolerant of carboplatindesensitization. Int J Gynecol Cancer2014;24:1603-1606. https://doi.org/10.1097/igc.0000000000000295.

  58. Dizon DS, Schwartz J, Rojan A, Miller J, PiresL, Disilvestro P, et al. Cross-sensitivity betweenpaclitaxel and docetaxel in a women's cancersprogram. Gynecol Oncol 2006;100:149-151.https://doi.org/10.1016/j.ygyno.2005.08.004.

  59. Sánchez-Muñoz A, Jiménez B, García-TapiadorA, Romero-García G, Medina L, NavarroV, et al. Cross-sensitivity between taxanes inpatients with breast cancer. Clin Transl Oncol2011;13:904-906. https://doi.org/10.1007/s12094-011-0753-3.

  60. Picard M, Pur L, Caiado J, Giavina-Bianchi P,Galvão VR, Berlin ST, et al. Risk stratificationand skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J AllergyClin Immunol 2016;137:1154-1164.e1112.https://doi.org/10.1016/j.jaci.2015.10.039.

  61. Pellegrino B, Boggiani D, Tommasi C, PalliD, Musolino A. Nab-paclitaxel after docetaxelhypersensitivity reaction: case report and literaturereview. Acta Biomed 2017;88:329-333.https://doi.org/10.23750/abm.v88i3.6138.

  62. Picard M. Management of hypersensitivityreactions to taxanes. Immunol Allergy ClinNorth Am 2017;37:679-693. https://doi.org/10.1016/j.iac.2017.07.004.

  63. Otani IM, Wong J, Banerji A. Platinum chemotherapyhypersensitivity: Prevalence andmanagement. Immunol Allergy Clin North Am2017;37:663-677. https://doi.org/10.1016/j.iac.2017.06.003.

  64. Markman M, Zanotti K, Peterson G, Kulp B,Webster K, Belinson J. Expanded experiencewith an intradermal skin test to predict forthe presence or absence of carboplatin hypersensitivity.J Clin Oncol 2003;21:4611-4614.https://doi.org/10.1200/jco.2003.05.539.

  65. Pagani M, Bavbek S, Dursun AB, BonadonnaP, Caralli M, Cernadas J, et al. Role of skin testsin the diagnosis of immediate hypersensitivityreactions to taxanes: Results of a multicenterstudy. J Allergy Clin Immunol Pract 2019;7:990-997. https://doi.org/10.1016/j.jaip.2018.09.018.

  66. Giavina-Bianchi P, Galvão VR, Picard M, CaiadoJ, Castells MC. Basophil activation test isa relevant biomarker of the outcome of rapiddesensitization in platinum compounds-allergy.J Allergy Clin Immunol Pract 2017;5:728-736.https://doi.org/10.1016/j.jaip.2016.11.006.

  67. Cernadas JR, Brockow K, Romano A, AbererW, Torres MJ, Bircher A, et al. General considerationson rapid desensitization for drug hypersensitivity- a consensus statement. Allergy2010;65:1357-1366. https://doi.org/10.1111/j.1398-9995.2010.02441.x.

  68. Kendirlinan R, Gümüşburun R, Çerçi P, ÖzbekE, Altıner S, Çelebi Sözener Z, et al.Rapid drug desensitization with chemotherapeutics(platins, taxanes, and others): A single-center retrospective study. Int Arch AllergyImmunol 2019;179:114-122. https://doi.org/10.1159/000496745.

  69. Caimmi S, Caffarelli C, Saretta F, Liotti L, CrisafulliG, Cardinale F, et al. Drug desensitizationin allergic children. Acta Biomed 2019;90:20-29.https://doi.org/10.23750/abm.v90i3-S.8158.

  70. Castells MC, Tennant NM, Sloane DE, Hsu FI,Barrett NA, Hong DI, et al. Hypersensitivity reactionsto chemotherapy: outcomes and safetyof rapid desensitization in 413 cases. J AllergyClin Immunol 2008;122:574-580. https://doi.org/10.1016/j.jaci.2008.02.044.

  71. Sloane D, Govindarajulu U, Harrow-MortellitiJ, Barry W, Hsu FI, Hong D, et al. Safety, costs,and efficacy of rapid drug desensitizations tochemotherapy and monoclonal antibodies. JAllergy Clin Immunol Pract 2016;4:497-504.https://doi.org/10.1016/j.jaip.2015.12.019.

  72. Karaatmaca B, Aytac S, Sahiner UM, SekerelBE, Soyer O. Successful oral desensitizationwith dasatinib in delayed cutaneous hypersensitivityreactions. Ann Allergy Asthma Immunol2019;123:216-217. https://doi.org/10.1016/j.anai.2019.05.011.

  73. Bavbek S, Lee MJ. Subcutaneous injectabledrugs hypersensitivity and desensitization:Insulin and monoclonal antibodies. ImmunolAllergy Clin North Am 2017;37:761-771.https://doi.org/10.1016/j.iac.2017.06.001.

  74. Demir S, Soyer O, Bilginer Y, Sag E, SahinerUM, Buyuktiryaki B, et al. Desensitisationovercomes rituximab- and tocilizumab-relatedimmediate hypersensitivity in childhood. ClinExp Rheumatol 2020;38:552-557.

  75. Lopez-Gonzalez P, Madrigal-Burgaleta R,Carpio-Escalona LV, Bernal-Rubio L, GuerraE, Berges-Gimeno MP, et al. Assessment ofantihistamines and corticosteroids as premedicationin rapid drug desensitization to paclitaxel:Outcomes in 155 procedures. J AllergyClin Immunol Pract 2018;6:1356-1362. https://doi.org/10.1016/j.jaip.2017.11.013.

  76. Fouda GE, Bavbek S. Rituximab hypersensitivity:From clinical presentation to management.Front Pharmacol 2020;11:572863. https://doi.org/10.3389/fphar.2020.572863.




2020     |     www.medigraphic.com